心脏移植还有未来吗?
本文综述心脏移植在晚期心力衰竭治疗中的地位与挑战。尽管药物治疗进步,心脏移植仍是晚期心衰最有效的持久治疗。供受体特征变化使决策更复杂,器官获取与保存、分配评分系统、ABO匹配及移植物失败防治仍是核心难题。离体灌注可能发挥重要作用,各国移植实践存在巨大差异。
要点
- 心脏移植仍是晚期心衰最有效的持久治疗
- 供受体特征变化使器官接受决策和术后管理更复杂
- 离体灌注可能改善器官保存并推动移植实践变革
核心结论
- 心脏移植仍是晚期心衰在死亡率和生活质量方面最有效的持久治疗。
- 供受体特征变化使器官接受决策、手术和术后管理更复杂。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 过去15年心衰仍是全球主要死因,患病率将持续上升。
- 多数Eurotransplant国家及其他主要移植网络移植数量持续上升,但有些国家停滞甚至下降(如德国)。
- 各国在晚期心衰使用机械循环辅助装置的实践因移植数量差异而显著不同。
关键数值与推荐
- 当前科学兴趣仍聚焦于器官获取与保存以减少缺血损伤、建立类似肺分配的分配评分系统、ABO血型抗原相容与不相容匹配、避免移植物失败和排斥及恶性肿瘤与心脏移植物血管病等二级疾病。
- 离体灌注(如Organ Care System®,TransMedics,Andover,MA,USA)可能在这一变化中发挥重要作用。
临床怎么用
- 临床决策需综合考虑变化的供受体特征及器官接受复杂性。
- 可关注离体灌注在器官保存中的应用潜力。
- 应认识到不同国家移植实践和机械循环支持使用的显著差异。
局限性
- 本文为综述,未报告系统检索策略、样本量或定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure has remained the leading cause of death globally for the last 15 years-and its prevalence will continue to rise. Fifty years ago, heart failure management was enriched by the possibility of a heart transplant. Despite impressive improvements in medical treatment for heart failure, a heart transplant remains the most effective long-lasting treatment for advanced heart failure in terms of mortality and quality of life. However, donor and recipient characteristics have changed dramatically in recent years, leading to more complex decision-making regarding organ acceptance and to more demanding operations and postoperative management. With improving pathophysiological understanding in the last decades, today's scientific interest still focuses on basic knowledge. How to retrieve and conserve organs to minimize ischaemic injury; how best to allocate them, considering the likelihood of success (developing a heart-allocation scoring system similar to that for lung allocation); how to match donor/recipient characteristics (ABO blood-group antigen compatibility versus incompatibility); and how to avoid graft failure, rejection and secondary morbidities such as malignomas and cardiac allograft vasculopathy after the heart transplant-all these factors remain fundamental challenges in today's transplant medicine. The use of ex vivo perfusion (e.g. via the Organ Care System®, TransMedics, Andover, MA, USA) may play an important role in this change. Remarkably, there are huge regional divergences in current transplant practices: Whereas the number of transplants continues to rise in most Eurotransplant countries and other major transplant networks, there are some countries in which transplant numbers are static or even dropping (as in Germany). This difference results in wide variations across different countries as to how advanced heart failure is treated using mechanical circulatory-assist devices.
引用
- Fuchs M, Schibilsky D, Zeh W, et al. Does the heart transplant have a future? Eur J Cardiothorac Surg. 2019. PMID: 31106338. doi:10.1093/ejcts/ezz107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。